Structure-activity relationship study around guanabenz identifies two derivatives retaining antiprion activity but having lost α2-adrenergic receptor agonistic activity

ACS Chemical Neuroscience

Volumn 5, Issue 10, 2014, Pages 1075-1082

  Nguyen, Phu Hai ^a   Hammoud, Hassan ^b   Halliez, Sophie ^c   Pang, Yanhong ^d   Evrard, Justine ^a   Schmitt, Martine ^b   Oumata, Nassima ^e   Bourguignon, Jean Jacques ^b   Sanyal, Suparna ^d   Beringue, Vincent ^c   Blondel, Marc ^a   Bihel, Frédéric ^b   Voisset, Cécile ^a  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b Faculté de Pharmacie   (France)

^c INRA Institut National de la Recherche Agronomique   (France)

^d UPPSALA UNIVERSITY   (Sweden)

^e Centre National de la Recherche Scientifique   (France)

Author keywords

Antiprion compounds; guanabenz; PrPSc prion protein; structure activity relationship study; yeast model for prion diseases; 2 adrenergic agonist

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BENZENE; CHLORINE; GUANABENZ; GUANIDINE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; NEUROPROTECTIVE AGENT; PRION; PRION PROTEIN;

ANIMAL CELL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG POTENCY; MOUSE; NONHUMAN; PRION DISEASE; PROTEIN FOLDING; RIBOSOME; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANIMAL; BOVINE; C57BL MOUSE; CEREBELLUM; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; ESCHERICHIA COLI; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PRION; PRION DISEASES; TISSUE CULTURE TECHNIQUE; TRANSGENIC MOUSE; YEAST;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ANIMALS; CATTLE; CEREBELLUM; CHO CELLS; CRICETULUS; ESCHERICHIA COLI; GUANABENZ; HUMANS; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; PRION DISEASES; PRIONS; PROTEIN FOLDING; PRPSC PROTEINS; RECEPTORS, ADRENERGIC, ALPHA-2; RIBOSOMES; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE CULTURE TECHNIQUES; YEASTS;

EID: 84908019225     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn5001588     Document Type: Article

References (44)

1. Kamatari, Y. O., Hayano, Y., Yamaguchi, K., Hosokawa-Muto, J., and Kuwata, K. (2013) Characterizing antiprion compounds based on their binding properties to prion proteins: implications as medical chaperones Protein Sci. 22, 22-34
2. Karapetyan, Y. E., Sferrazza, G. F., Zhou, M., Ottenberg, G., Spicer, T., Chase, P., Fallahi, M., Hodder, P., Weissmann, C., and Lasmezas, C. I. (2013) Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents Proc. Natl. Acad. Sci. U.S.A. 110, 7044-7049
3. Oumata, N., Nguyen, P. H., Beringue, V., Soubigou, F., Pang, Y., Desban, N., Massacrier, C., Morel, Y., Paturel, C., Contesse, M. A., Bouaziz, S., Sanyal, S., Galons, H., Blondel, M., and Voisset, C. (2013) The toll-like receptor agonist imiquimod is active against prions PLoS One 8, e72112
4. Sim, V. L. (2012) Prion disease: chemotherapeutic strategies Infect. Disord.: Drug Targets 12, 144-160
5. Tribouillard-Tanvier, D., Beringue, V., Desban, N., Gug, F., Bach, S., Voisset, C., Galons, H., Laude, H., Vilette, D., and Blondel, M. (2008) Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions PLoS One 3, e1981
6. Boyce, M., Bryant, K. F., Jousse, C., Long, K., Harding, H. P., Scheuner, D., Kaufman, R. J., Ma, D., Coen, D. M., Ron, D., and Yuan, J. (2005) A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress Science 307, 935-939
7. Liebman, S. W. and Chernoff, Y. O. (2012) Prions in yeast Genetics 191, 1041-1072
8. Bach, S., Talarek, N., Andrieu, T., Vierfond, J. M., Mettey, Y., Galons, H., Dormont, D., Meijer, L., Cullin, C., and Blondel, M. (2003) Isolation of drugs active against mammalian prions using a yeast-based screening assay Nat. Biotechnol. 21, 1075-1081
9. Bach, S., Tribouillard, D., Talarek, N., Desban, N., Gug, F., Galons, H., and Blondel, M. (2006) A yeast-based assay to isolate drugs active against mammalian prions Methods 39, 72-77
10. Chattopadhyay, S., Das, B., and Dasgupta, C. (1996) Reactivation of denatured proteins by 23S ribosomal RNA: role of domain V Proc. Natl. Acad. Sci. U.S.A. 93, 8284-8287
11. Das, B., Chattopadhyay, S., Bera, A. K., and Dasgupta, C. (1996) In vitro protein folding by ribosomes from Escherichia coli, wheat germ and rat liver: the role of the 50S particle and its 23S rRNA Eur. J. Biochem. 235, 613-621
12. Das, D., Das, A., Samanta, D., Ghosh, J., Dasgupta, S., Bhattacharya, A., Basu, A., Sanyal, S., and Das Gupta, C. (2008) Role of the ribosome in protein folding Biotechnol. J. 3, 999-1009
13. Voisset, C., Thuret, J. Y., Tribouillard-Tanvier, D., Saupe, S. J., and Blondel, M. (2008) Tools for the study of ribosome-borne protein folding activity Biotechnol. J. 3, 1033-1040
14. Tsaytler, P., Harding, H. P., Ron, D., and Bertolotti, A. (2011) Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis Science 332, 91-94
15. Moreno, J. A., Radford, H., Peretti, D., Steinert, J. R., Verity, N., Martin, M. G., Halliday, M., Morgan, J., Dinsdale, D., Ortori, C. A., Barrett, D. A., Tsaytler, P., Bertolotti, A., Willis, A. E., Bushell, M., and Mallucci, G. R. (2012) Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration Nature 485, 507-511
16. Barbezier, N., Chartier, A., Bidet, Y., Buttstedt, A., Voisset, C., Galons, H., Blondel, M., Schwarz, E., and Simonelig, M. (2011) Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy EMBO Mol. Med. 3, 35-49
17. Brundin, P., Melki, R., and Kopito, R. (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases Nat. Rev. Mol. Cell Biol. 11, 301-307
18. Costanzo, M. and Zurzolo, C. (2013) The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration Biochem. J. 452, 1-17
19. Frost, B. and Diamond, M. I. (2010) Prion-like mechanisms in neurodegenerative diseases Nat. Rev. Neurosci. 11, 155-159
20. Goedert, M., Clavaguera, F., and Tolnay, M. (2010) The propagation of prion-like protein inclusions in neurodegenerative diseases Trends Neurosci. 33, 317-325
21. Jucker, M. and Walker, L. C. (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases Nature 501, 45-51
22. Vaccaro, A., Patten, S. A., Aggad, D., Julien, C., Maios, C., Kabashi, E., Drapeau, P., and Parker, J. A. (2013) Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo Neurobiol. Dis. 55, 64-75
23. Holmes, B., Brogden, R. N., Heel, R. C., Speight, T. M., and Avery, G. S. (1983) Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension Drugs 26, 212-229
24. Schafer, S. G., Kaan, E. C., Christen, M. O., Low-Kroger, A., Mest, H. J., and Molderings, G. J. (1995) Why imidazoline receptor modulator in the treatment of hypertension? Ann. N.Y. Acad. Sci. 763, 659-672
25. Sica, D. A. (2007) Centrally acting antihypertensive agents: an update J. Clin. Hypertens. 9, 399-405
26. Archer, F., Bachelin, C., Andreoletti, O., Besnard, N., Perrot, G., Langevin, C., Le Dur, A., Vilette, D., Baron-Van Evercooren, A., Vilotte, J. L., and Laude, H. (2004) Cultured peripheral neuroglial cells are highly permissive to sheep prion infection J. Virol. 78, 482-490
27. Vilotte, J. L., Soulier, S., Essalmani, R., Stinnakre, M. G., Vaiman, D., Lepourry, L., Da Silva, J. C., Besnard, N., Dawson, M., Buschmann, A., Groschup, M., Petit, S., Madelaine, M. F., Rakatobe, S., Le Dur, A., Vilette, D., and Laude, H. (2001) Markedly increased susceptibility to natural sheep scrapie of transgenic mice expressing ovine prp J. Virol. 75, 5977-5984
28. Fernandez-Acero, T., Rodriguez-Escudero, I., Vicente, F., Monteiro, M. C., Tormo, J. R., Cantizani, J., Molina, M., and Cid, V. J. (2012) A yeast-based in vivo bioassay to screen for class I phosphatidylinositol 3-kinase specific inhibitors J. Biomol Screening 17, 1018-1029
29. Piletz, J. E., Zhu, H., and Chikkala, D. N. (1996) Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes J. Pharmacol. Exp. Ther. 279, 694-702
30. Pang, Y., Kurella, S., Voisset, C., Samanta, D., Banerjee, D., Schabe, A., Das Gupta, C., Galons, H., Blondel, M., and Sanyal, S. (2013) The antiprion compound 6-Aminophenanthridine inhibits protein folding activity of the ribosome by direct competition J. Biol. Chem. 288, 19081-19089
31. Reis, S. D., Pang, Y., Vishnu, N., Voisset, C., Galons, H., Blondel, M., and Sanyal, S. (2011) Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding Biochimie 93, 1047-1054
32. Tribouillard-Tanvier, D., Dos Reis, S., Gug, F., Voisset, C., Beringue, V., Sabate, R., Kikovska, E., Talarek, N., Bach, S., Huang, C., Desban, N., Saupe, S. J., Supattapone, S., Thuret, J. Y., Chedin, S., Vilette, D., Galons, H., Sanyal, S., and Blondel, M. (2008) Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs PLoS One 3, e2174
33. Kudlicki, W., Coffman, A., Kramer, G., and Hardesty, B. (1997) Ribosomes and ribosomal RNA as chaperones for folding of proteins Folding Des. 2, 101-108
34. Sanyal, S. C., Bhattacharyya, D., and Das Gupta, C. (2002) The folding of dimeric cytoplasmic malate dehydrogenase. Equilibrium and kinetic studies Eur. J. Biochem. 269, 3856-3866
35. Falsig, J., Sonati, T., Herrmann, U. S., Saban, D., Li, B., Arroyo, K., Ballmer, B., Liberski, P. P., and Aguzzi, A. (2012) Prion pathogenesis is faithfully reproduced in cerebellar organotypic slice cultures PLoS Pathog. 8, e1002985
36. Falsig, J. and Aguzzi, A. (2008) The prion organotypic slice culture assay - POSCA Nat. Protoc 3, 555-562
37. Tribouillard, D., Bach, S., Gug, F., Desban, N., Beringue, V., Andrieu, T., Dormont, D., Galons, H., Laude, H., Vilette, D., and Blondel, M. (2006) Using budding yeast to screen for anti-prion drugs Biotechnol. J. 1, 58-67
38. Bavadekar, S. A., Ma, G., Mustafa, S. M., Moore, B. M., Miller, D. D., and Feller, D. R. (2006) Tethered yohimbine analogs as selective human alpha2C-adrenergic receptor ligands J. Pharmacol. Exp. Ther. 319, 739-748
39. Eason, M. G., Kurose, H., Holt, B. D., Raymond, J. R., and Liggett, S. B. (1992) Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C2 adrenergic receptors to Gi and Gs J. Biol. Chem. 267, 15795-15801
40. Regan, J. W., Kobilka, T. S., Yang-Feng, T. L., Caron, M. G., Lefkowitz, R. J., and Kobilka, B. K. (1988) Cloning and expression of a human kidney cDNA for an alpha 2-adrenergic receptor subtype Proc. Natl. Acad. Sci. U.S.A. 85, 6301-6305
41. Ederth, J., Mandava, C. S., Dasgupta, S., and Sanyal, S. (2009) A single-step method for purification of active His-tagged ribosomes from a genetically engineered Escherichia coli Nucleic Acids Res. 37, e15
42. Le Dur, A., Beringue, V., Andreoletti, O., Reine, F., Lai, T. L., Baron, T., Bratberg, B., Vilotte, J. L., Sarradin, P., Benestad, S. L., and Laude, H. (2005) A newly identified type of scrapie agent can naturally infect sheep with resistant PrP genotypes Proc. Natl. Acad. Sci. U.S.A. 102, 16031-16036
43. Deslys, J. P., Comoy, E., Hawkins, S., Simon, S., Schimmel, H., Wells, G., Grassi, J., and Moynagh, J. (2001) Screening slaughtered cattle for BSE Nature 409, 476-478
44. Feraudet, C., Morel, N., Simon, S., Volland, H., Frobert, Y., Creminon, C., Vilette, D., Lehmann, S., and Grassi, J. (2005) Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells J. Biol. Chem. 280, 11247-11258